Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484204 | 0.84 | SMN1; SMN2 (0.48) | POLBMAPK1ADRA1DADRA1AADRA1B | |
| SCHEMBL5480222 | 0.84 | POLB (0.57) | POLBMAPK1ADRA1DADRA1AADRA1B | |
| SCHEMBL5482189 | 0.82 | POLB (0.47) | POLBMAPK1SMN1; SMN2MEN1HTR7 | |
| SCHEMBL5477807 | 0.76 | POLB (0.55) | POLBMAPK1MEN1KMT2A | |
| SCHEMBL5482627 | 0.72 | POLB (0.53) | POLBMAPTMEN1CYP2C9CYP2C19 | |
| SCHEMBL19561754 | 0.72 | MAPK1 (0.80) | MAPK1HTR7KMT2A | |
| SCHEMBL8152227 | 0.72 | ATM (0.52) | POLBMAPTMGLLMEN1CYP1A2 | |
| SCHEMBL5474190 | 0.72 | ENPP2 (0.51) | POLBMAPTSMN1; SMN2MGLLMEN1 | |
| SCHEMBL11431546 | 0.72 | MGLL (0.57) | POLBMAPTSMN1; SMN2MGLLMEN1 | |
| SCHEMBL13533230 | 0.70 | ADRA1D (0.77) | MAPK1ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | POLB 2709/4885MAPK1 1/4885ADRA1D 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.